These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28483342)

  • 21. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
    Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU
    Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Patient treated with pirfenidone].
    Valenzuela C
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():19-20. PubMed ID: 23630973
    [No Abstract]   [Full Text] [Related]  

  • 23. Two therapies now available for idiopathic pulmonary fibrosis.
    Morrow T
    Manag Care; 2014 Dec; 23(12):47-8. PubMed ID: 25939185
    [No Abstract]   [Full Text] [Related]  

  • 24. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
    King TE; Albera C; Bradford WZ; Costabel U; du Bois RM; Leff JA; Nathan SD; Sahn SA; Valeyre D; Noble PW
    Am J Respir Crit Care Med; 2014 Apr; 189(7):825-31. PubMed ID: 24476390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis].
    Kashiwada T; Azuma A
    Nihon Naika Gakkai Zasshi; 2016 Jun; 105(6):970-6. PubMed ID: 30168687
    [No Abstract]   [Full Text] [Related]  

  • 26. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 27. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs.
    Kingwell K
    Nat Rev Drug Discov; 2014 Jul; 13(7):483-4. PubMed ID: 24981347
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
    Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
    Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New guideline on treatment of idiopathic pulmonary fibrosis.
    Spagnolo P; Bonella F; Maher TM
    Lancet Respir Med; 2015 Sep; 3(9):e31-e32. PubMed ID: 26380887
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA panel likes new treatment for idiopathic pulmonary fibrosis.
    Morrow T
    Manag Care; 2010 Apr; 19(4):53-4. PubMed ID: 20446566
    [No Abstract]   [Full Text] [Related]  

  • 31. The changing treatment landscape in idiopathic pulmonary fibrosis.
    Costabel U
    Eur Respir Rev; 2015 Mar; 24(135):65-8. PubMed ID: 25726557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung transplantation for idiopathic pulmonary fibrosis.
    Le Pavec J; Dauriat G; Gazengel P; Dolidon S; Hanna A; Feuillet S; Pradere P; Crutu A; Florea V; Boulate D; Mitilian D; Fabre D; Mussot S; Mercier O; Fadel E
    Presse Med; 2020 Jun; 49(2):104026. PubMed ID: 32437844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new era of drug therapy for idiopathic pulmonary fibrosis.
    Crooks MG; Hart SP
    Lancet Respir Med; 2014 Dec; 2(12):964-6. PubMed ID: 25466348
    [No Abstract]   [Full Text] [Related]  

  • 35. Pirfenidone for idiopathic pulmonary fibrosis.
    Bouros D
    Lancet; 2011 May; 377(9779):1727-9. PubMed ID: 21571363
    [No Abstract]   [Full Text] [Related]  

  • 36. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
    Sathiyamoorthy G; Sehgal S; Ashton RW
    South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Poletti V; Ravaglia C; Tomassetti S
    Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
    King CS; Nathan SD
    Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
    [No Abstract]   [Full Text] [Related]  

  • 40. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
    Brown KK
    Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.